Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Luminari

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
American Journal of Hematology|October 21, 2014
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana LinfomiGiuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
Journal of Geriatric Oncology|July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana LinfomiFrancesco Merli, Federica Cavallo, Flavia Salvi, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Haematologica|January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL studyDavide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Blood Advances|January 15, 2020
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphomaArmando Santoro, Rita Mazza, Alessandro Pulsoni, et al.
Ocular Immunology and Inflammation|August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined ChemotherapyFabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
American Journal of Hematology|October 21, 2014
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana LinfomiGiuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
Journal of Geriatric Oncology|July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana LinfomiFrancesco Merli, Federica Cavallo, Flavia Salvi, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Haematologica|January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL studyDavide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Blood Advances|January 15, 2020
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphomaArmando Santoro, Rita Mazza, Alessandro Pulsoni, et al.
Ocular Immunology and Inflammation|August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined ChemotherapyFabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Pageof 21